The ABPI welcomes the Government’s announcement to invest an extra £2billion a year in to science research and development by the end of this parliament. The ABPI also welcomes the government’s commitment to support and invest in science and technology innovation through its industrial strategy and looks forward to hearing more about how it will ensure the UK becomes the best place in the world to support the discovery, clinical development and use of innovative medicines.
ABPI, Chief Executive, Mike Thompson, said:
The Prime Minister has spoken about the strategic importance of the pharmaceutical industry in the UK and today we've seen a commitment to creating an industrial strategy which supports science and innovation.
As we look ahead to the Autumn Statement on Wednesday, reports today of an extra £2 billion of funding a year for the sector will help to ensure this becomes a reality.
This is hugely welcome and will be well received by everybody involved in UK life-sciences.
Given the right support, the NHS has the infrastructure to become the go-to place for companies to research, develop and use new medicines.
Working with the pharmaceutical industry and other partners the NHS can capitalise on its unique ability to access clinical data.
By using anonymous patient data safely and effectively we can help make the UK the best place in the world to support the clinical development and use of innovative medicines.
The next wave of medical technologies has the potential to bring investment, highly skilled jobs and improved healthcare for patients.
Investment in both will benefit patients, the NHS and help secure the future of the UK life sciences sector.
We will continue to work with government to build an industrial strategy with life-sciences at its heart and look forward to further dialogue as we head towards the March Budget."
Notes to editors